Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: wlheatmoon who wrote (55)	12/1/1999 11:34:00 PM
From: Carolyn	Read Replies (1) \| Respond to of 2850

Gee, this is right up my alley. My husband was a urologist. I'm going to call a bunch tomorrow and ask about this.

To: wlheatmoon who wrote (55)	12/3/1999 1:01:00 PM
From: John Pitera	Read Replies (2) \| Respond to of 2850

NMPS-- Biotech-- Cancer Screening -- New Way To Use NMP Test for Early Detection of Cervical PreMalignancies. I did not see this new potential usage for NMPS's Nuclear Protein Matrix screening technique as the next development in the NMPS story. But it is a positive one. NMPS could end up with a very Large revenue stream if their products can be used for so many cancer screenings. John ------------------------------------ PRECLINICAL STUDY REPORTS MATRITECH'S NMP179(TM) 'MAY BE AN EFFECTIVE MARKER FOR THE EARLY DETECTION' OF CERVICAL PREMALIGNANCIES FINDINGS reported in the November-December issue of Acta Cytologica "NMP179 showed high sensitivity for the detection of precancer, especially with regard to advanced cases(96.7%). This is significant since these are the preneoplastic lesions most likely to progress to invasive cancer." Martha Hutchinson, Ph.D., M.D. Director of Cytopathology Women and Infants' Hospital, Providence, R.I. PR NEWSWIRE - December 03, 1999 07:59 NEWTON, Mass., Dec 3, 1999 /PRNewswire via COMTEX/ -- Matritech Inc. (Nasdaq: NMPS), a company specializing in products designed to detect, manage and screen cancer, announced today that a pre-clinical study reported in the November-December 1999 issue of Acta Cytologica reported that its cervical cancer test, NMP179(TM), was reliable and highly accurate in detecting pre-invasive lesions that could progress to cervical cancer. The blinded study by Brigham and Women's Hospital (Boston, Mass.) and Women and Infants' Hospital (Providence, R.I.) evaluated 261 cervical cytology specimens. NMP179 detected 96.7 percent of cases diagnosed as high-grae squamous intraepithelial lesions (HSIL). "We are encouraged by the clinical performance of NMP179 in the early identification of women at high risk of developing cervical cancer," said David L. Corbet, President and Chief Operating Officer of Matritech. "Acta Cytologica is among the preeminent peer-reviewed journals in the field of cytology. The report of NMP179's performance in a journal of this stature is further confirmation of the clinical potential of this NMP-based product. "According to the American Cancer Society, cervical cancer will kill 4, 800 women this year. The potential early predictive value of NMP179 offers new hope in the fight against the disease because, according to the International Federation of Gynecology and Obstetrics, the survival rate for cervical cancer is 91 percent when discovered in early stages," Corbet continued. The data from the study published in Acta Cytologica support the recent findings from a subsequent investigation of NMP179. In a separate pilot study presented in late 1998 at the annual meeting of the American Society of Cytopathology, physicians at New England Medical Center in Boston, as well as scientists at Matritech, reported that the NMP179 test identified 100 percent of atypical Pap smears that contained both hidden high-grade precancerous lesions (HSIL), as well as those that would later progress to HSIL Matritech Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein (NMP) technology, discovered at the Massachusetts Institute of Technology and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast and prostate cancers. Matritech's nuclear matrix protein (NMP) technology platform correlates levels of NMPs in body fluids and tissues to the presence of cancer. Multiple published clinical studies have validated this ability of NMPs to detect early-stage cancerous abnormalities. Matritech has a deep pipeline of NMP-based products in pre-clinical and clinical development SOURCE Matritech Inc. (C) 1999 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Stephen D. Chubb, CEO or David L. Corbet, President of Matritech, Inc., 617-928-0820 or Derek Caldwell, Investor Relations of Sunrise Financial Group, 212-421-1616 or Steve Danehy, Media Relations of Ronald Trahan Associates, Inc., 617-332-0101 WEB PAGE: matritech.com GEOGRAPHY: Massachusetts / ------------------------------------------------------------

To: wlheatmoon who wrote (55)	12/3/1999 2:30:00 PM
From: John Pitera	Read Replies (1) \| Respond to of 2850

NMPS--Biotech--Cancer Detection-- John Hopkins Researcher to Collaborate with NMPS on a Prostrate Cancer Test. Dr Alan Partin, is Editor-In-Chief of the Journal of Urology. Urology is the Primary Journal for these guys. (Boldly Restatement of what Mike said, Read the post I am Responding too NMPS is a company with a 85 million market cap today with it selling for 4.00 a share. John ------------------ Tuesday October 19, 9:39 am Eastern Time Company Press Release SOURCE: Matritech, Inc. Matritech and Johns Hopkins Researcher Collaborate to Develop Prostate Cancer Test "... the expression of YL-1 appears to be related to aggressive prostate cancer, suggesting a potential marker ..." Excerpted from The Journal of Urology April 1998 NEWTON, Mass., Oct. 19 /PRNewswire/ -- Matritech, Inc. (Nasdaq: NMPS - news) announced today that it has entered into a collaboration with Alan Partin, M.D., Ph.D., of the Johns Hopkins University School of Medicine, to develop a new prostate cancer test that has the potential to differentiate between aggressive and low-grade disease, thereby indicating the extent of treatment necessary and improving the patient's quality of life. The novel, proprietary prostate cancer test will measure the amount of a YL-1, a nuclear matrix protein (NMP), a high expression of which has been found in prostate cancer tissue with a high Gleason score. A high Gleason score is an indicator of aggressive disease. A preliminary study by investigators of the Johns Hopkins School of Medicine, published in the April 1998 issue of The Journal of Urology, found that the incidence of YL-1 is associated with the poor prognosis prostate cancers. ``Analysis of 39 human prostate cancer specimens has demonstrated a specific nuclear matrix protein, YL-1, present in the majority of aggressive tumors and which was not seen in any of the 10 normal prostates,' according to the Johns Hopkins investigators who conducted the study. ``We are very pleased to be working with Dr. Partin, one of the pioneers in prostate cancer treatment,' said David L. Corbet, President and Chief Operating Officer of Matritech. ``Currently we believe there is no reliable, cost-effective test to determine which prostate cancer patients are at the highest risk for disease progression and, therefore, would require radical treatment. This nuclear matrix protein, YL-1, has the potential to fill that void. ``We have collaborated with Dr. Partin on several investigations of nuclear matrix proteins in the past and look forward to continuing that productive relationship,' added Corbet. ``Although much further study is required, YL-1 has the potential to impact prostate cancer therapy and thereby spare some patients the potential complications of aggressive treatment.' According to the American Cancer Society, prostate cancer is the second-leading cause of cancer death in men. There were an estimated 179,300 new cases of prostate cancer in the United States in 1999. Although an estimated 37,000 prostate cancer patients died in 1999, the five-year survival rate is 100 percent when the disease is detected early. The most life threatening, late-stage forms of prostate cancer often require surgical removal of the prostate, which can lead to complications such as impotence and incontinence. Matritech's core technology is based on the detection of cancer related nuclear matrix proteins (NMPs) that are detected in body fluids or cells. Levels of these proteins can correlate with the presence of cancer, even at early stages. The Company is developing and commercializing innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, cervical, colon, breast and prostate cancers. The NMP22© Test Kit for bladder cancer has been cleared by the U.S. FDA for monitoring patients who have previously been treated for bladder cancer, and is under review for testing symptomatic, but previously undiagnosed bladder cancer patients. NMP22 is also approved for detection and management of bladder cancer in China and in Japan. The test is also in use in Europe. In addition to the NMP22 Test Kit, the Company has developed an NMP179(TM) cervical cancer kit, a NuMA(TM) Colon Cancer Test Kit, and has products for breast and prostate cancer under development.